Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
884.13B
Market cap884.13B
Price-Earnings ratio
41.59
Price-Earnings ratio41.59
Dividend yield
0.65%
Dividend yield0.65%
Average volume
3.25M
Average volume3.25M
High today
$957.69
High today$957.69
Low today
$930.02
Low today$930.02
Open price
$946.61
Open price$946.61
Volume
2.73M
Volume2.73M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 884.13B, Eli Lilly(LLY) trades at $935.95. The stock has a price-to-earnings ratio of 41.59 and currently yields dividends of 65.3%.

During the trading session on 2026-04-02, Eli Lilly(LLY) shares reached a daily high of $957.69 and a low of $930.02. At a current price of $935.95, the stock is +0.6% higher than the low and still -2.3% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 2.73M, versus its average volume of 3.25M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Simply Wall St 5h
Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate

Eli Lilly (NYSE:LLY) received U.S. FDA approval for Foundayo, its first oral, once-daily GLP-1 weight loss pill for obesity and overweight patients with related...

Eli Lilly’s Foundayo Pill Resets Obesity Portfolio And Valuation Debate
TipRanks 6h
Ro says working with Eli Lilly to launch Zepbound KwikPen

Direct-to-patient healthcare company Ro announced that it is working with Eli Lilly (LLY) to launch the recently FDA-approved Zepbound KwikPen nationwide on its...

Investor's Business Daily 9h
How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch

Stocks With Rising Composite Ratings: Eli Lilly 4/01/2026 Eli Lilly saw an improvement in its IBD SmartSelect Composite Rating Thursday, from 93 to 96. 4/01/2...

How Novo Nordisk Is Striking Back As Eli Lilly Plans Its Newest Weight-Loss Launch

Analyst ratings

83%

of 35 ratings
Buy
82.9%
Hold
14.3%
Sell
2.9%

More LLY News

Benzinga 10h
Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh

Eli Lilly And Company (NYSE:LLY) shares are down approximately 1% Thursday despite FDA approval of its oral weight-loss drug Foundayo on Wednesday, as geopoliti...

Eli Lilly Stock Slips Despite Foundayo Approval As Geopolitical Tensions Weigh
Nasdaq 12h
Lilly Surges 3.8%: Is This an Indication of Further Gains?

Eli Lilly (LLY) shares rallied 3.8% in the last trading session to close at $954.52. This move can be attributable to notable volume with a higher number of sha...

Lilly Surges 3.8%: Is This an Indication of Further Gains?
TipRanks 13h
Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly Challenge

Shares in Danish drugmaking giant Novo Nordisk (NVO) — already down about 26% since the start of the year — are now facing even more pressure after American arc...

The Motley Fool 15h
Prediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.)

The spotlight has been on Eli Lilly (LLY +3.84%) in recent years as the pharma player constructed a very valuable portfolio: one focused on diabetes and weight...

Prediction: This Will Be Eli Lilly's Next Billion-Dollar Growth Driver. (Hint: It's Not Weight Loss Drugs.)
Nasdaq 1d
Why Eli Lilly Stock Trounced the Market Today

Key Points It will compete directly with a similar product from rival Novo Nordisk. It remains to be seen which pill American users will prefer. 10 stocks we...

Why Eli Lilly Stock Trounced the Market Today
Nasdaq 1d
FDA Approves Eli Lilly's Foundayo Weight-Loss Pill

(RTTNews) - The U.S. Food and Drug Administration has given the green light to Foundayo, a new daily weight-loss pill from Eli Lilly and Company, which shakes t...

FDA Approves Eli Lilly's Foundayo Weight-Loss Pill
Seeking Alpha 1d
Lilly CEO says new GLP-1 pill's scalability will help expand global reach

Eli Lilly (LLY) CEO Dave Ricks said the company's newly approved GLP-1 pill, Foundayo, will help expand Lilly's reach in the global weight-loss market in part b...

Lilly CEO says new GLP-1 pill's scalability will help expand global reach

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.